vs
Side-by-side financial comparison of MOBIX LABS, INC (MOBX) and Instil Bio, Inc. (TIL). Click either name above to swap in a different company.
Instil Bio, Inc. is the larger business by last-quarter revenue ($2.2M vs $1.9M, roughly 1.2× MOBIX LABS, INC). Instil Bio, Inc. runs the higher net margin — -365.3% vs -540.0%, a 174.7% gap on every dollar of revenue. On growth, Instil Bio, Inc. posted the faster year-over-year revenue change (-19.2% vs -40.8%).
Instil Bio Inc. is a clinical-stage biotechnology company focused on developing innovative tumor-infiltrating lymphocyte (TIL) therapies for patients with difficult-to-treat advanced solid tumors. It operates in the immuno-oncology segment, serving patient populations that show limited response to existing standard cancer treatment options.
MOBX vs TIL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9M | $2.2M |
| Net Profit | $-10.1M | $-8.2M |
| Gross Margin | 31.0% | — |
| Operating Margin | -471.1% | -426.3% |
| Net Margin | -540.0% | -365.3% |
| Revenue YoY | -40.8% | -19.2% |
| Net Profit YoY | 49.0% | 31.1% |
| EPS (diluted) | $-0.16 | $-1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.9M | $2.2M | ||
| Q3 25 | $1.9M | $2.2M | ||
| Q2 25 | $2.4M | $2.2M | ||
| Q1 25 | $2.5M | $2.2M | ||
| Q4 24 | $3.2M | $2.8M | ||
| Q3 24 | $3.0M | $1.5M | ||
| Q2 24 | $2.1M | $0 | ||
| Q1 24 | $1.1M | $0 |
| Q4 25 | $-10.1M | $-8.2M | ||
| Q3 25 | $-15.7M | $-13.6M | ||
| Q2 25 | $-8.3M | $-21.4M | ||
| Q1 25 | $-2.3M | $-28.2M | ||
| Q4 24 | $-19.8M | $-11.9M | ||
| Q3 24 | $-11.5M | $-23.0M | ||
| Q2 24 | $-7.7M | $-14.9M | ||
| Q1 24 | $-1.8M | $-24.3M |
| Q4 25 | 31.0% | — | ||
| Q3 25 | 50.5% | — | ||
| Q2 25 | 57.4% | — | ||
| Q1 25 | 40.6% | — | ||
| Q4 24 | 53.2% | — | ||
| Q3 24 | 56.6% | — | ||
| Q2 24 | 35.5% | — | ||
| Q1 24 | 16.9% | — |
| Q4 25 | -471.1% | -426.3% | ||
| Q3 25 | -834.9% | -670.0% | ||
| Q2 25 | -343.4% | -1045.5% | ||
| Q1 25 | -311.7% | -1363.2% | ||
| Q4 24 | -461.7% | -426.1% | ||
| Q3 24 | -378.0% | -1582.8% | ||
| Q2 24 | -454.2% | — | ||
| Q1 24 | -747.8% | — |
| Q4 25 | -540.0% | -365.3% | ||
| Q3 25 | -835.8% | -606.0% | ||
| Q2 25 | -352.0% | -954.2% | ||
| Q1 25 | -91.2% | -1257.8% | ||
| Q4 24 | -626.0% | -428.8% | ||
| Q3 24 | -390.6% | -1541.9% | ||
| Q2 24 | -373.1% | — | ||
| Q1 24 | -153.1% | — |
| Q4 25 | $-0.16 | $-1.13 | ||
| Q3 25 | $-0.26 | $-2.01 | ||
| Q2 25 | $-0.17 | $-3.24 | ||
| Q1 25 | $-0.06 | $-4.32 | ||
| Q4 24 | $-0.52 | $-1.82 | ||
| Q3 24 | $-0.33 | $-3.54 | ||
| Q2 24 | $-0.25 | $-2.29 | ||
| Q1 24 | $-0.21 | $-3.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $6.6M |
| Total DebtLower is stronger | $6.3M | — |
| Stockholders' EquityBook value | $4.7M | $113.9M |
| Total Assets | $32.7M | $203.5M |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $6.6M | ||
| Q3 25 | — | $5.8M | ||
| Q2 25 | — | $7.7M | ||
| Q1 25 | — | $15.4M | ||
| Q4 24 | — | $8.8M | ||
| Q3 24 | — | $6.7M | ||
| Q2 24 | — | $6.8M | ||
| Q1 24 | — | $5.5M |
| Q4 25 | $6.3M | — | ||
| Q3 25 | $6.2M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $4.6M | — | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $3.4M | — | ||
| Q2 24 | $3.2M | — | ||
| Q1 24 | $3.2M | — |
| Q4 25 | $4.7M | $113.9M | ||
| Q3 25 | $-336.0K | $120.4M | ||
| Q2 25 | $425.0K | $131.7M | ||
| Q1 25 | $342.0K | $144.9M | ||
| Q4 24 | $-3.0M | $169.4M | ||
| Q3 24 | $5.5M | $176.3M | ||
| Q2 24 | $8.5M | $195.0M | ||
| Q1 24 | $4.2M | $205.8M |
| Q4 25 | $32.7M | $203.5M | ||
| Q3 25 | $37.1M | $211.8M | ||
| Q2 25 | $34.6M | $231.0M | ||
| Q1 25 | $36.5M | $237.4M | ||
| Q4 24 | $37.3M | $263.6M | ||
| Q3 24 | $39.1M | $272.6M | ||
| Q2 24 | $41.3M | $294.3M | ||
| Q1 24 | $29.5M | $306.3M |
| Q4 25 | 1.34× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 10.26× | — | ||
| Q1 25 | 13.44× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.62× | — | ||
| Q2 24 | 0.38× | — | ||
| Q1 24 | 0.76× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.8M | $-7.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.8M | $-7.1M | ||
| Q3 25 | $-4.5M | $-10.6M | ||
| Q2 25 | $-4.1M | $-14.8M | ||
| Q1 25 | $-586.0K | $-4.2M | ||
| Q4 24 | $-930.0K | $-10.6M | ||
| Q3 24 | $-3.6M | $-20.1M | ||
| Q2 24 | $-3.1M | $-10.6M | ||
| Q1 24 | $-8.1M | $-14.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-4.6M | — | ||
| Q2 24 | $-3.1M | — | ||
| Q1 24 | $-9.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -157.1% | — | ||
| Q2 24 | -151.8% | — | ||
| Q1 24 | -794.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 34.5% | 0.0% | ||
| Q2 24 | 2.2% | — | ||
| Q1 24 | 87.3% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MOBX
| US | $1.7M | 92% |
| Other | $155.0K | 8% |
TIL
Segment breakdown not available.
